Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies

被引：9

作者：

Al-Juhaishi, Taha ^{[1
]}

Ahmed, Sairah ^{[1
,2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplant & Cell Therapy, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

来源：

CURRENT HEMATOLOGIC MALIGNANCY REPORTS | 2021年 / 16卷 / 01期

关键词：

Chimeric antigen receptor T-cell (CAR-T); B-cell lymphoma; Cytokine release syndrome; CAR-NK; Novel CAR-T constructs;

D O I：

10.1007/s11899-021-00615-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Chimeric antigen receptor T-cell (CAR-T) therapy is a form of adoptive cellular therapy that has revolutionized the treatment landscape in hematologic malignancies, especially B-cell lymphomas. In this review, we will discuss some of the landmark data behind these therapies and then lay out our approach to utilizing this new therapy. Recent Findings CD19-directed CAR-Ts are the most common type currently used in treatment of relapsed B-cell lymphoid neoplasms. There are currently three FDA-approved products: axicabtagene ciluecel and tisagenlecleucel for the treatment of relapsed/refractory large B-cell lymphoma and pediatric B-cell acute lymphocytic leukemia (tisagenlecleucel only) and brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. These therapies are associated with distinctive acute toxicities such as cytokine release syndrome and neurotoxicity and chronic toxicities such as cytopenias and hypogammaglobulinemia. CAR-T therapy provides significant potential in the treatment of relapsed B-cell lymphomas despite current limitations. Several novel CAR cell designs are currently being studied in clinical trials which include tandem CAR-Ts, allogeneic CAR-Ts, and CAR-NK cells.

引用

页码：32 / 39

页数：8

共 61 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2]

Abramson Jeremy S, 2019, Am Soc Clin Oncol Educ Book, V39, P446, DOI 10.1200/EDBK_238693

[3]

Aftab BT., 2020, ADV CELL GENE THER, V3, P86

[4]

[Anonymous], CANC STAT FACTS NONH

[5] Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy [J].

Bachanova, Veronika ;

Perales, Miguel-Angel ;

Abramson, Jeremy S. .

BLOOD REVIEWS, 2020, 40

[6]

Brentjens, 2020, NAT REV CLIN ONCOL

[7] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease [J].

Brudno, Jennifer N. ;

Somerville, Robert P. T. ;

Shi, Victoria ;

Rose, Jeremy J. ;

Halverson, David C. ;

Fowler, Daniel H. ;

Gea-Banacloche, Juan C. ;

Pavletic, Steven Z. ;

Hickstein, Dennis D. ;

Lu, Tangying L. ;

Feldman, Steven A. ;

Iwamoto, Alexander T. ;

Kurlander, Roger ;

Maric, Irina ;

Goy, Andre ;

Hansen, Brenna G. ;

Wilder, Jennifer S. ;

Blacklock-Schuver, Bazetta ;

Hakim, Frances T. ;

Rosenberg, Steven A. ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1112-+

[8] Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study [J].

Casulo, Carla ;

Byrtek, Michelle ;

Dawson, Keith L. ;

Zhou, Xiaolei ;

Farber, Charles M. ;

Flowers, Christopher R. ;

Hainsworth, John D. ;

Maurer, Matthew J. ;

Cerhan, James R. ;

Link, Brian K. ;

Zelenetz, Andrew D. ;

Friedberg, Jonathan W. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) :2516-U55

[9] Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation [J].

Chen, Yuhong ;

Cheng, Yifei ;

Suo, Pan ;

Yan, Chenhua ;

Wang, Yu ;

Chen, Yao ;

Han, Wei ;

Xu, Lanping ;

Zhang, Xiaohui ;

Liu, Kaiyan ;

Chang, Lungji ;

Xiao, Lei ;

Huang, Xiaojun .

BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (04) :598-605

[10] Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells [J].

Cordeiro, Ana ;

Bezerra, Evandro D. ;

Hirayama, Alexandre V. ;

Hill, Joshua A. ;

Wu, Qian V. ;

Voutsinas, Jenna ;

Sorror, Mohamed L. ;

Turtle, Cameron J. ;

Maloney, David G. ;

Bar, Merav .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) :26-33

← 1 2 3 4 5 6 7 →